NY-based strategic consulting firm Research Nester launched global market research for psychedelic substances with projections until 2035.
Top players featured include known names such as COMPASS Pathways (NASDAQ:CMPS), Silo Pharma (NASDAQ:SILO), Numinus Wellness (OTC:NUMIF), Cybin (NYSE:CYBN), Mind Medicine (MindMed) (NASDAQ:MNMD), PharmaTher Holdings (OTC:PHRRF) and atai Life Sciences (NASDAQ:ATAI); yet also general biotech industry heavyweights like Jazz Pharmaceuticals (NASDAQ:JAZZ), Janssen Pharmaceuticals (NYSE:JNJ) and Pfizer (NYSE:PFE).
The global market's size is predicted to grow at a CAGR of around 14% in the next 12 years, garnering a revenue of $12 billion by the end of 2035, up from 2022's $3 billion.
Context And Key Takeaways
As most pharmaceutical market projections do, the research contemplates the COVID pandemic's effects in terms of a rise in demand for psychedelic drugs to treat mental health issues, either new or enhanced by the situation.
Stress, anxiety and depression spread globally due to uncertainty for the future, jobs and income loss, social isolation and fear of virus transmission, it found.
The increased demand was exacerbated by the impossibility of accessing traditional forms of therapy due to lockdown. On the other hand, the pandemic reduced production costs, allowing manufacturers to gain higher profit margins and increase the psychedelic drugs market size.
Recent years' research into psychedelics' potential therapeutic benefits for diverse mental health conditions as well as for general well-being took many pharmaceutical companies and research institutions to increase their focus on developing psychedelic-based treatments.
Analysts found that, in 2021, nearly $2 billion were invested in the psychedelics sector, vouching for more R&D and the corresponding costly clinical trials. In the next couple of years, increasing venture capitalists' investment along with more patent filings for psychedelic-related drugs and collaborations between academic institutions and pharmaceutical companies would further boost the market's growth.
Key points:
The North American market is potentially the one with the largest revenue by the end of 2033. Specifically with PTSD, but also due to the growing prevalence and incidence of depression, anxiety disorders, schizophrenia, eating disorders and addictions (see 2022's staggering numbers.)
The Asia Pacific market, for its part, would be the one growing at the highest rate by 2033, following a rise in mental health awareness and "the rising focus" of governments on the improvement of healthcare infrastructure and the increasing prevalence of mental disorders such as depression in the region.
In the end-user segment, hospitals would hold the largest revenue by the end of 2033.
Other market segmentations include drugs and type; source; and administration routes.
Into the cannabis industry? Then our imminent Cannabis Capital Conference is where you ought to be! Whether to close your deals or just get acquainted with the sector's best, come join us on Sept. 27-28 in Chicago for our 17th edition.
總部位於紐約的戰略諮詢公司 研究內斯特 啓動了迷幻藥物的全球市場研究 到 2035 年的預測。
精選頂級玩家 包括已知的名字,例如 指南針之路 (納斯達克股票代碼:CMPS), 筒倉製藥 (納斯達克股票代碼:SILO), 努米努斯健康 (OTC: NUMIF), Cybin (紐約證券交易所代碼:CYBN), 心靈醫學(MindMed) (納斯達克股票代碼:MNMD), 藥明控股 (場外交易代碼:PHRRF)和 阿泰生命科學 納斯達克股票代碼:ATAI);還有普通生物技術行業的重量級人物,比如 爵士製藥 (納斯達克股票代碼:JAZZ), 詹森製藥 (紐約證券交易所代碼:JNJ)和 輝瑞公司 (紐約證券交易所代碼:PFE)。
預計全球市場的規模將以 複合年增長率約爲14% 在接下來的12年中,到2035年底將獲得120億美元的收入,高於 2022 年的 30 億美元。
背景和關鍵要點
正如大多數製藥市場的預測一樣,該研究考慮了COVID大流行的影響,即對治療心理健康問題的迷幻藥物的需求增加,無論是新的還是因情況而加劇的。
研究發現,由於未來的不確定性、工作和收入損失、社會孤立以及對病毒傳播的恐懼,壓力、焦慮和抑鬱在全球範圍內蔓延。
由於封鎖,無法獲得傳統形式的治療,這加劇了需求的增長。另一方面,大流行 降低生產成本,使製造商能夠獲得更高的利潤率並擴大迷幻藥的市場規模。
近年來,對迷幻藥對各種心理健康狀況和總體健康的潛在治療益處的研究花了很多時間 製藥公司和研究機構 讓他們更加專注於開發基於迷幻藥的治療方法。
分析師發現,在 2021 年,將近 20 億美元 投資於迷幻藥領域,爲更多的研發和相應的研發提供了擔保 昂貴的臨床試驗。在未來幾年中,增加風險投資家的投資,增加迷幻藥相關藥物的專利申請,以及學術機構與製藥公司之間的合作,將進一步推動市場的增長。
關鍵點:
這個 北美市場 可能是那個帶有 收入最大 到 2033 年底。具體來說 創傷後應激障礙,也是由於抑鬱症、焦慮症、精神分裂症、飲食失調和成癮的患病率和發病率不斷上升(見 2022的數字令人震驚。)
這個 亞太市場,就其本身而言,它將是那個正在成長的 最高費率 到2033年,在此之前,心理健康意識有所提高,各國政府 “越來越關注” 改善醫療基礎設施,以及該地區抑鬱症等精神疾病的患病率不斷上升。
在 最終用戶細分市場,醫院將持有 收入最大 到 2033 年底。
其他細分市場包括藥物和類型、來源和給藥途徑。
進入大麻行業?然後我們的 即將舉行的大麻資本會議 是你應該去的地方!無論是要完成交易還是隻是想了解該行業的最佳人物,請於9月27日至28日在芝加哥加入我們,參加我們的第17版。